Skip to content
Screener

QuidelOrtho Corporation QDEL Royalty and License Expenses

Royalty and License Expenses at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
10%0.0pp
Caleres logo
CaleresCAL
$2.03M+5.7%
Universal Display logo
Universal DisplayOLED
$54.21M-26.3%
Microvision logo
MicrovisionMVIS
$18K-77.8%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$1.94M-93.0%
Regenxbio logo
RegenxbioRGNX
$1.04M-80.0%

Other financials

Income statement

See full
Revenue$630.9M+2.8%
Gross profit$272.9M-0.7%
Operating income-$21.8M+87.9%
Net income-$92.9M+63.6%
EPS (diluted)-$1.36+63.9%

Balance sheet

See full
Cash & equivalents$123.4M-18.7%
Total debt$3.4B+3.0%
Total equity$1.8B-36.4%
Total assets$5.7B-10.4%

Cash flow

See full
Operating cash flow-$110.6M
CapEx$25.5M-32.0%
Free cash flow-$136.1M-61.4%

Valuation

See full
Market cap$942.91M-41.3%
Enterprise value$4.25B-11.2%
P/S0.4×-0.2×

Profitability

See full
Gross margin44.6%-2.7pp
Operating margin-30.8%-49.9pp
Net margin-39.2%-168pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-45.9%-94.9pp
Debt / equity1.9×+0.7×
Current ratio1.4×+0.3×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept qdel:RoyaltyAndLicenseExpenses.

The source filing: QuidelOrtho Corporation’s 10-K, filed February 19, 2026.

Filed
Feb 18, 2026, 9:45 PM EST
Fiscal year
FY2025
Accession
0001906324-26-000008

The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales, as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $14.0 million, $18.5 million and $21.8 million for fiscal years ended 2025, 2024 and 2023, respectively.

Item 8. Financial Statements and Supplementary Data

FAQ

What is QuidelOrtho Corporation's royalty and license expenses?
QuidelOrtho Corporation (QDEL) reported royalty and license expenses of $3.5M in Q4 2025.
How has QuidelOrtho Corporation's royalty and license expenses changed year-over-year?
QuidelOrtho Corporation's royalty and license expenses decreased by 24.3% year-over-year, from $4.63M to $3.5M.
What is the long-term trend for QuidelOrtho Corporation's royalty and license expenses?
Over 2 years (2023 to 2025), QuidelOrtho Corporation's royalty and license expenses has grown at a -19.9% compound annual growth rate (CAGR), from $21.8M to $14M.
What does royalty and license expenses mean?
Royalty and License Expenses as reported by QuidelOrtho Corporation Common Stock.

Ask your AI about QuidelOrtho Corporation's royalty and license expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude